Search

Author/Creator Friesenhahn, Michel

1. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. (22nd May 2018)

Authors:
Cummings, Jeffrey L.; Cohen, Sharon; van Dyck, Christopher H.; Brody, Mark; Curtis, Craig; Cho, William; Ward, Michael; Friesenhahn, Michel; Rabe, Christina; Brunstein, Flavia; Quartino, Angelica; Honigberg, Lee A.; Fuji, Reina N.; Clayton, David; Mortensen, Deborah; Ho, Carole; Paul, Robert
Journal:
Neurology
Issue:
Volume 90:Number 21(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening. Issue 4 (23rd September 2022)

Authors:
Rabe, Christina; Bittner, Tobias; Jethwa, Alexander; Suridjan, Ivonne; Manuilova, Ekaterina; Friesenhahn, Michel; Stomrud, Erik; Zetterberg, Henrik; Blennow, Kaj; Hansson, Oskar
Journal:
Alzheimer's & dementia
Issue:
Volume 19:Issue 4(2023)
Page Start:
1393
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. O4‐11‐06: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE. (1st July 2014)

Authors:
Cummings, Jeffrey; Cho, William; Ward, Michael; Friesenhahn, Michel; Brunstein, Flavia; Honigberg, Lee; Clayton, David; Mortensen, Deborah; Ho, Carole; Paul, Robert
Journal:
Alzheimer's & dementia
Issue:
Volume 10:Supplement 4S(2014)Part 5
Page Start:
P275
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗